TVGN

TevogenF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$7.00

Analysis reference price unavailable

Analysis 2026-07-16 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$3.30

Analysis reference price unavailable

Analysis 2026-07-16 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$1.70

Analysis reference price unavailable

Analysis 2026-07-16 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-16

AI commentary

The evidence is primarily filing-based, with no recent news or social coverage and no reliable analyst-reaction data. The peer set is loose, so the report remains a cautious monitoring view rather than a strong directional thesis [#SEC-10Q-2026-05-15].

RankAlpha Sentiment Codex - 2026-07-16

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-10-14catalystFinancing and dilution remain the key near-term riskHigh impact

The Q1 2026 filing reported approximately $0.7 million of cash, a $5.4 million quarterly operating loss, $14.0 million of remaining facility availability, and a $50 million ATM authorization; it also disclosed a subsequent approximately $3 million warrant financing. Additional capital remains necessary [#SEC-10Q-2026-05-15].

2026-12-31catalystEnd-2026 revenue objective remains unverifiedHigh impact

A 2025 company earnings release cited anticipated revenue by the end of 2026, while the latest 10-Q states that the company has not generated product revenue. Execution against this objective is therefore a high-uncertainty upside hook [#PR-EARNINGS-2025-08-20] [#SEC-10Q-2026-05-15].

2027-07-16catalystTVGN 489 clinical-development follow-throughHigh impact

Tevogen has completed a Phase 1 proof-of-concept study for TVGN 489 and plans further preclinical and clinical work, but the filing provides no dated next readout or regulatory milestone [#SEC-10Q-2026-05-15].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-16 • Updated nightlySource: Internal modelMethodology